S&P 500
7,715.73
+49.13
+0.64%
Dow
53,544.87
+482.92
+0.91%
Nasdaq
26,460.86
+243.03
+0.93%
NYSE Composite
24,660.63
+165.08
+0.67%
Russell 2000
2,971.75
+18.59
+0.63%
VIX
15.03
-0.17
-1.12%
RARE · Ultragenyx Pharmaceutical Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Ultragenyx Pharmaceutical Inc (RARE)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$14.65
-11.90
(-44.80%)
● Market open
DAY'S RANGE
$14.65
$13.84
$14.90
52-WEEK RANGE
$14.65
$18.29
$39.89
What's happening
- RARE is down 44.80% today, trading at $14.65. — Live quote
- It's trading within 3% of its 52-week low ($18.29). (Finnhub fundamentals)
- Volume today (221,533) is well below its 3-month average of 2,208,340. (Finnhub fundamentals)
- Last quarter's EPS beat estimates: $-0.90 actual vs. $-1.24 estimated (+27.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 14
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (26 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RARE
+15.35%
vs S&P 500
+3.14%
1-YEAR RETURN
RARE
-15.91%
vs S&P 500
-34.77%
6-MONTH RETURN
RARE
+13.42%
3-MONTH RETURN
RARE
+21.81%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-08-04 (Q2 2026)
$-0.90
Est. $-1.24
BEAT +27.4%
2026-04-26 (Q1 2026)
$-1.84
Est. $-1.54
MISS -19.5%
2026-01-26 (Q4 2025)
$-1.29
Est. $-1.11
MISS -15.8%
2025-10-26 (Q3 2025)
$-1.81
Est. $-1.26
MISS -43.7%
Valuation Measures & Ratios
Enterprise Value4$3.63B
Forward P/E5—
PEG Ratio6-0.78
Price / Sales (TTM1)3.65
Price / Book7316.50
EV4 / Revenue5.07
EV4 / EBITDA—
Profit Margin-81.73%
Operating Margin-73.67%
Return on Equity (ROE8)-414.17%
Return on Assets (ROA9)-44.37%
Avg Volume (3M)2,208,340
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $3.41B | $2.10B | $3.00B | $3.57B | $3.49B |
| P/E | -5.96 | -3.33 | -5.17 | -6.73 | -5.94 |
| Price/Sales | 5.04 | 3.49 | 4.95 | 6.03 | 6.52 |
| Price/Book | -11.73 | -8.91 | 327.25 | 23.67 | 24.21 |
| EV/Revenue | 4.86 | 3.20 | 4.62 | 5.74 | 6.29 |
| EV/EBITDA | -6.71 | -3.46 | -5.39 | — | — |
| ROE | 196.71% | 267.55% | -6331.79% | -351.73% | -407.50% |
| ROA | -45.29% | -48.72% | -48.72% | -40.66% | -44.73% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short15,887,767
Change from Prior Settlement+6.18%
% of Float—
Days to Cover (Short Ratio)7.78
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 28.5% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -81.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -15.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RARE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $214.0M | $136.0M | $159.9M | $167.0M | $139.0M | $139.5M | $147.0M | $108.8M |
| Operating income | -$75.0M | -$169.0M | -$170.9M | -$108.0M | -$143.0M | -$132.0M | -$116.4M | -$165.3M |
| Net income | -$92.0M | -$185.0M | -$180.4M | -$115.0M | -$151.0M | -$133.5M | -$131.6M | -$170.7M |
| EPS (diluted) | $-0.90 | $-1.84 | $-1.81 | $-1.17 | $-1.57 | $-1.40 | $-1.52 | $-2.03 |
| EPS (basic) | $-0.90 | $-1.84 | $-1.81 | $-1.17 | $-1.57 | $-1.40 | $-1.52 | $-2.03 |
| Operating margin | -$35 | -$124 | -$107 | -$65 | -$103 | -$95 | -$79 | -$152 |
| Net margin | -$43 | -$136 | -$113 | -$69 | -$109 | -$96 | -$90 | -$157 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.26B | $1.30B | $1.53B | $1.19B | $1.31B | $1.31B | $1.50B | $1.54B |
| Total liabilities | $1.55B | $1.52B | $1.60B | $1.17B | $1.15B | $1.16B | $1.24B | $1.18B |
| Stockholders' equity | -$291.0M | -$236.0M | -$80.0M | $9.2M | $151.0M | $144.0M | $255.0M | $346.8M |
| Total current assets | $606.0M | $657.0M | $951.0M | $643.2M | $719.8M | $699.2M | $817.0M | $799.6M |
| Total current liabilities | $351.0M | $325.0M | $384.0M | $340.0M | $293.2M | $291.7M | $344.0M | $285.0M |
| Cash & equivalents | $125.0M | $175.0M | $421.0M | $202.5M | $176.0M | $127.0M | $174.0M | $150.6M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $200.0M | $121.0M | $158.0M | $112.5M | $124.5M | $98.8M | $122.0M | $93.3M |
| Inventory | $59.0M | $55.0M | $52.0M | $52.2M | $46.5M | $46.0M | $45.0M | $43.3M |
| Other current assets | — | — | — | — | — | — | — | $41.4M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $235.0M | $239.0M | $244.0M | $250.0M | $255.8M | $260.9M | $266.0M | $272.4M |
| Goodwill | $44.0M | $44.0M | $44.0M | $44.4M | $44.4M | $44.4M | $44.0M | $44.4M |
| Intangible assets | $172.0M | $174.0M | $176.0M | $172.9M | $174.7M | $176.5M | $178.0M | $164.9M |
| Other non-current assets | $63.0M | $61.0M | $60.0M | $57.9M | $60.1M | $62.4M | $63.0M | $53.9M |
| Accounts payable | $39.0M | $42.0M | $31.0M | $40.6M | $34.2M | $47.5M | $39.0M | $36.0M |
| Accrued liabilities | $221.0M | $194.0M | $265.0M | $220.5M | $180.8M | $173.0M | $241.0M | $185.0M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | $15.0M | $17.0M | $19.0M | $1.2M | $2.6M | $3.3M | $4.0M | $4.8M |
| Other non-current liabilities | $41.0M | $42.0M | $44.0M | $18.8M | $17.4M | $17.1M | $17.0M | $16.1M |
| Common stock & paid-in capital | $0 | $0 | $0 | $96.0K | $96.0K | $94.0K | $0 | $92.0K |
| Retained earnings | -$4.81B | -$4.72B | -$4.53B | -$4.40B | -$4.22B | -$4.11B | -$3.96B | -$3.82B |
| Accumulated other comprehensive income (loss) | $0 | $0 | $1.0M | $820.0K | -$268.0K | -$341.0K | -$1.0M | $896.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$97.0M | -$197.0M | -$99.8M | -$91.2M | -$109.0M | -$166.0M | -$79.3M | -$67.0M |
| Investing cash flow | $44.0M | -$49.0M | -$72.2M | $117.2M | $71.0M | $120.0M | $102.5M | -$275.5M |
| Financing cash flow | $3.0M | — | $394.2M | -$192.0K | $83.8M | $157.0K | $2.9M | $11.2M |
| Free cash flow | -$98.0M | -$198.0M | -$100.8M | -$92.2M | -$112.0M | -$167.0M | -$79.5M | -$68.6M |
| Capital expenditures | $1.0M | $1.0M | $938.0K | $1.1M | $3.0M | $1.0M | $163.0K | $1.6M |
| Depreciation & amortization | $8.0M | $8.0M | $8.8M | $8.2M | $9.0M | $9.0M | $9.5M | $8.8M |
| Share-based compensation | — | — | — | — | — | — | — | — |
| Deferred income taxes | — | — | — | — | — | — | -$1.0M | — |
| Change in accounts receivable | $62.0M | -$19.0M | $33.8M | -$5.8M | $13.0M | -$10.0M | $21.0M | -$9.8M |
| Change in inventory | $3.0M | $4.0M | -$150.0K | $5.2M | $0 | $1.0M | $2.2M | $2.5M |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $57.0M | $131.0M | $153.6M | $16.4M | $16.0M | $0 | $16.3M | $367.4M |
| Sales/maturities of investments | $38.0M | — | -$143.0K | $143.0K | -$92.0K | $92.0K | -$148.0K | $126.0K |
| Other investing activities | $3.0M | $0 | -$273.0K | $1.3M | -$1.0M | $1.0M | -$309.0K | $203.0K |
| Dividends paid | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | $0 | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M |
| Operating income | -$535.0M | -$536.0M | -$569.0M | -$648.9M | -$381.7M |
| Net income | -$575.0M | -$569.0M | -$607.0M | -$707.4M | -$454.0M |
| EPS (diluted) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
| EPS (basic) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
| Operating margin | -$79 | -$96 | -$131 | -$179 | -$109 |
| Net margin | -$85 | -$102 | -$140 | -$195 | -$129 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.53B | $1.50B | $1.49B | $1.55B | $1.52B |
| Total liabilities | $1.60B | $1.24B | $1.22B | $1.19B | $599.8M |
| Stockholders' equity | -$80.0M | $255.0M | $275.0M | $352.0M | $922.6M |
| Total current assets | $951.0M | $817.0M | $732.2M | $883.9M | $856.6M |
| Total current liabilities | $384.0M | $344.0M | $280.4M | $261.2M | $181.4M |
| Cash & equivalents | $421.0M | $174.0M | $214.0M | $132.9M | $307.6M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $158.0M | $122.0M | $73.4M | $40.4M | $28.4M |
| Inventory | $52.0M | $45.0M | $34.0M | $26.8M | $16.2M |
| Other current assets | — | — | $47.6M | $68.9M | — |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $244.0M | $266.0M | $290.6M | $259.7M | $141.2M |
| Goodwill | $44.0M | $44.0M | $44.4M | $44.4M | $44.4M |
| Intangible assets | $176.0M | $178.0M | $166.3M | $160.1M | $130.8M |
| Other non-current assets | $60.0M | $63.0M | $57.7M | $48.3M | $20.6M |
| Accounts payable | $31.0M | $39.0M | $42.1M | $43.3M | $17.1M |
| Accrued liabilities | $265.0M | $241.0M | $196.5M | $204.7M | $145.6M |
| Deferred revenue (current) | — | — | — | — | $9.1M |
| Other current liabilities | $7.0M | $4.0M | $0 | — | — |
| Other non-current liabilities | $20.0M | $17.0M | $12.2M | $4.8M | $1.0M |
| Common stock & paid-in capital | $0 | $0 | $82.0K | $70.0K | $69.0K |
| Retained earnings | -$4.53B | -$3.96B | -$3.39B | -$2.78B | -$2.07B |
| Accumulated other comprehensive income (loss) | $1.0M | -$1.0M | $647.0K | -$6.6M | -$1.4M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$466.0M | -$414.0M | -$475.0M | -$380.5M | -$338.7M |
| Investing cash flow | $236.0M | -$18.0M | $168.0M | -$291.7M | -$195.4M |
| Financing cash flow | $478.0M | $399.0M | $388.0M | $501.2M | $118.6M |
| Free cash flow | -$472.0M | -$421.0M | -$519.0M | -$496.6M | -$411.8M |
| Capital expenditures | $6.0M | $7.0M | $44.0M | $116.1M | $73.1M |
| Depreciation & amortization | $35.0M | $36.0M | $26.0M | $18.2M | $13.2M |
| Share-based compensation | — | — | — | — | — |
| Deferred income taxes | — | -$1.0M | -$2.0M | $1.6M | — |
| Change in accounts receivable | $31.0M | $34.0M | $23.0M | $12.1M | $5.4M |
| Change in inventory | $6.0M | $11.0M | $7.0M | $9.7M | $3.1M |
| Change in accounts payable | — | — | — | — | — |
| Purchases of investments | $186.0M | $409.0M | $526.0M | $614.7M | $1.01B |
| Sales/maturities of investments | $0 | $3.0M | $51.0M | $84.3M | $92.9M |
| Other investing activities | $1.0M | $2.0M | $6.0M | $844.0K | $942.0K |
| Other financing activities | $0 | $0 | $1.0M | -$555.0K | -$492.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RARE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-06 to 2026-08-03
Recent transactions
- Insiders have net sold 44,822 shares over the last 182 days, across 0 purchases and 12 sales.
- Most recent: Parschauer Karah Herdman (EVP and Chief Legal Officer) — Open market sale of 1,900 shares on 2026-08-03.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)44,822 sh(12 txns)
Net Shares-44,822
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Parschauer Karah Herdman | EVP and Chief Legal Officer | Open market sale | 2026-08-03 | 1,900 |
| Horn Howard | Chief Financial Officer | Open market sale | 2026-08-03 | 4,696 |
| Sanders Corazon (Corsee) D. | Reporting person | Open market sale | 2026-06-15 | 2,000 |
| SULIMAN SHEHNAAZ | Reporting person | Open market sale | 2026-05-18 | 5,740 |
| Fust Matthew K | Reporting person | Grant / award | 2026-05-14 | 7,751 |
| Ray Amrit | Reporting person | Grant / award | 2026-05-14 | 7,751 |
| NARACHI MICHAEL | Reporting person | Grant / award | 2026-05-14 | 7,751 |
| WELCH DANIEL G | Reporting person | Grant / award | 2026-05-14 | 7,751 |
| Dunsire Deborah | Reporting person | Grant / award | 2026-05-14 | 7,751 |
| Crombez Eric | EVP and Chief Medical Officer | Open market sale | 2026-05-05 | 344 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | Grant / award | 2026-04-22 | 20,241 |
| KAKKIS EMIL D | President & CEO | Grant / award | 2026-04-16 | 76,745 |
| Huang Dennis Karl | See Remarks | Grant / award | 2026-04-16 | 23,116 |
| Pinion John Richard | See Remarks | Grant / award | 2026-04-16 | 23,116 |
| Harris Erik | EVP & Chief Commercial Officer | Grant / award | 2026-04-16 | 28,895 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-03 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Open market sale | 1,900 | $24.92 |
| 2026-08-03 | Horn Howard | Chief Financial Officer | Open market sale | 4,696 | $24.92 |
| 2026-07-01 | Horn Howard | Chief Financial Officer | Open market sale | 4,698 | $33.13 |
| 2026-06-15 | Sanders Corazon (Corsee) D. | Reporting person | Open market sale | 2,000 | $25.05 |
| 2026-06-15 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Open market sale | 1,899 | $24.62 |
| 2026-06-01 | Horn Howard | Chief Financial Officer | Open market sale | 4,653 | $23.77 |
| 2026-05-18 | SULIMAN SHEHNAAZ | Reporting person | Open market sale | 5,740 | $25.12 |
| 2026-05-14 | Fust Matthew K | Reporting person | Grant / award | 7,751 | $0.00 |
| 2026-05-14 | SULIMAN SHEHNAAZ | Reporting person | Grant / award | 7,751 | $0.00 |
| 2026-05-14 | Ray Amrit | Reporting person | Grant / award | 7,751 | $0.00 |
| 2026-05-14 | Sanders Corazon (Corsee) D. | Reporting person | Grant / award | 7,751 | $0.00 |
| 2026-05-14 | NARACHI MICHAEL | Reporting person | Grant / award | 7,751 | $0.00 |
| 2026-05-14 | WELCH DANIEL G | Reporting person | Grant / award | 7,751 | $0.00 |
| 2026-05-14 | Dunsire Deborah | Reporting person | Grant / award | 7,751 | $0.00 |
| 2026-05-05 | Crombez Eric | EVP and Chief Medical Officer | Open market sale | 344 | $24.96 |
| 2026-05-01 | Horn Howard | Chief Financial Officer | Open market sale | 4,683 | $24.90 |
| 2026-04-22 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Grant / award | 20,241 | $0.00 |
| 2026-04-16 | KAKKIS EMIL D | President & CEO | Grant / award | 76,745 | $0.00 |
| 2026-04-16 | Huang Dennis Karl | See Remarks | Grant / award | 23,116 | $0.00 |
| 2026-04-16 | Pinion John Richard | See Remarks | Grant / award | 23,116 | $0.00 |
| 2026-04-16 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Grant / award | 28,895 | $0.00 |
| 2026-04-16 | Harris Erik | EVP & Chief Commercial Officer | Grant / award | 28,895 | $0.00 |
| 2026-04-16 | Crombez Eric | EVP and Chief Medical Officer | Grant / award | 34,674 | $0.00 |
| 2026-04-16 | Horn Howard | Chief Financial Officer | Grant / award | 34,674 | $0.00 |
| 2026-04-01 | Horn Howard | Chief Financial Officer | Open market sale | 4,683 | $20.97 |
| 2026-03-10 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Open market sale | 3,508 | $22.67 |
| 2026-03-06 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Open market sale | 6,018 | $21.40 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 13:52 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-02 | 8-K | 2026-09-02 | View on SEC.gov → |
| 2026-08-19 | 8-K | 2026-08-19 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-01 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-05-18 | 4 | 2026-05-14 | View on SEC.gov → |
Recent news
Headlines about RARE (Ultragenyx Pharmaceutical Inc.). Links open the publisher — we don’t host full articles.
-
Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls
Yahoo Finance · 2026-09-03 -
Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 47% Drop.
Yahoo Finance · 2026-09-03 -
Wondering what's happening in today's pre-market session?
ChartMill · 2026-09-03 -
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Yahoo Finance · 2026-09-03 -
Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint
Yahoo Finance · 2026-09-03 -
RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades – This Analyst Sees Another Problem Ahead
Yahoo Finance · 2026-09-03 -
Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
Seeking Alpha · 2026-09-03 -
Why Did RARE Stock Slump 46% After-Hours?
Yahoo Finance · 2026-09-02
No headlines in this category right now — try “All”.